Search PubMed⌕ Search

Biomedical subjects

G Stark

Publications and source records attributed to G Stark.

201 records · Page 12Linked to original sources

Comparison of acute electrophysiological effects of amiodarone and its metabolite desethylamiodarone in Langendorff perfused guinea pig hearts.

During long-term treatment with amiodarone, slowing of conduction through the atrioventricular node, a prolongation of the QT-interval, and a prolongation of the atrial and ventricular myocardial refractoriness always developed. During short-term treatment, these effects were not found, except for depression of the AV-nodal conduction. This led to the suggestion that the electrophysiological effects of amiodarone during long-term treatment might be partly the result of the accumulation of its metabolite desethylamiodarone. Therefore, we examined the electrophysiological effects of amiodarone and desethylamiodarone on conduction and refractoriness in isolated spontaneously beating guinea pig hearts perfused by the method of Langendorff. Within 1 h of perfusion, desethylamiodarone caused a more pronounced prolongation of the AV-nodal, His-bundle, and intraventricular conduction intervals than did amiodarone. Desethylamiodarone, but not amiodarone led to a prolongation of the QT-interval. The refractoriness of sinoatrial-, AV-nodal conduction, and of the atrial myocardium were significantly more prolonged by amiodarone than by desethylamiodarone. Both compounds showed a comparable strong rate-dependent effect on AV-nodal refractoriness. The ventricular refractoriness was similarily prolonged by either compound. These results show that for the class-III effects (i.e., prolongation of repolarization period) observed under chronic treatment of amiodarone the metabolite desethylamiodarone may be responsible. Desethylamiodarone also exerts more pronounced effects on the fast-channel-dependent parts of the conduction system than does amiodarone, a fact indicated by a higher prolongation of His-bundle and intraventricular conduction.

Amiodarone↗

An update on chronic myeloid leukaemia.

The therapy of CML is clearly 'work in progress' Although long-term follow-up data for patients treated with STI571 are not yet available, preliminary results are encouraging. STI571 is likely to be licensed in late 2001/early 2002 and will certainly find a place in the treatment of CML. Current therapeutic considerations are summarised in Fig 2. At all stages of treatment it is vital that the patient is fully aware of treatment options, their risks and benefits. In some cases there is little evidence to suggest that one treatment option is better than another; in these situations, treatment is likely to depend on a patient's individual circumstances and preferences.

Antineoplastic Agents↗